Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director
CC transcript

Steel Excel Inc. (ADPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/10/2023 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
05/02/2023 4 STEEL PARTNERS HOLDINGS L.P. (10% Owner) has filed a Form 4 on Steel Connect, Inc.
Txns: Granted 112,043 options to buy @ $1.1, valued at $123.2k
Granted 3,387,957 options to buy @ $1.1, valued at $3.7M
02/13/2023 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
11/15/2022 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
08/15/2022 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
05/11/2022 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
02/11/2022 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
11/16/2021 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
08/16/2021 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
05/14/2021 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
04/27/2021 GN Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
03/17/2021 GN Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen
03/05/2021 GN Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
02/25/2021 GN Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
02/23/2021 GN Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
02/23/2021 GN Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
02/12/2021 13F-NT Form 13F-NT - Quarterly report filed by institutional managers, Notice:
02/03/2021 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/28/2021 SC 13D/A Steel Excel Inc. reports a 7.8% stake in Aviat Networks, Inc.
01/27/2021 4 Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.
Txns: Sold 31,787 shares @ $37.8513, valued at $1.2M
01/11/2021 GN Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
12/30/2020 GN Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/22/2020 SC 13D/A Steel Excel Inc. reports a 10.1% stake in Aviat Networks, Inc.
12/21/2020 4 Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.
Txns: Sold 464 shares @ $37.9491, valued at $17.6k
Sold 5,400 shares @ $37.0002, valued at $199.8k
12/17/2020 4 Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.
Txns: Sold 35,100 shares @ $37.3059, valued at $1.3M
12/17/2020 SC 13D/A Steel Excel Inc. reports a 10.2% stake in Aviat Networks, Inc.
12/16/2020 4 Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.
Txns: Sold 27,159 shares @ $37.5305, valued at $1M
Sold 24,128 shares @ $37.5086, valued at $905k
12/14/2020 SC 13D/A Steel Excel Inc. reports a 11.3% stake in Aviat Networks, Inc.
12/11/2020 4 Steel Excel Inc. (10% Owner) has filed a Form 4 on AVIAT NETWORKS, INC.
Txns: Sold 10,244 shares @ $40.5022, valued at $414.9k
Sold 14,000 shares @ $38.0075, valued at $532.1k
12/06/2020 GN Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
11/23/2020 GN Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy